Skip to content

Main Navigation

Clinical Study

Selexipag: A Drug to Study for Children and Adolescences with Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension (PAH) is a type of high blood pressure that affects the arteries in the lungs and heart. Selexipag is an approved drug for adults with PAH. Research is needed to know if the drug is safe and effective for children and adolescents with PAH. The information we learn may aid future patients.


For more information contact:

Lisa Hansen
  (801) 587-9104

IRB#: IRB_00135477 | PI: Ronald Day | Department: PEDIATRIC CARDIOLOGY | Approval Date: 2020-12-02 07:00:00
Study Categories: Heart Studies | Specialties: Pediatric Cardiology

Who can participate?

 Gender: All

 Age: All Ages

 Volunteers: Volunteers with special conditions

 Location: In Person

Inclusion Criteria:

  • Ages 2-18
  • Parent(s) with legal authorization to sign on behalf of the participant
  • PAH diagnosis
  • In-person at the University of Utah

Exclusion Criteria:

  • PAH diagnosis related to other specific diseases
  • Previous use of the drug
  • Any surgery related to PAH
  • Use of a medical device within 4 weeks of participation

Will I be paid for my time?


Last Updated: 4/5/21